Lupin Plans To Bring New Class Of Diabetes Drug To India

Lupin plans to bring new class of diabetes drug to India

Lupin plans to bring new class of diabetes drug to India

Mumbai: Lupin Ltd, India’s second largest pharmaceutical company, is looking to enhance its diabetes drugs offering in the domestic market by bringing in a new class of drugs through the in-licensing route, a senior company official said.
Under in-licensing, a company gets a licence to market a product of another company in one or more geographies.
Lupin’s current diabetes products’ basket includes different classes of drugs such as oral hypoglycemic agents (OHAs), insulins and novel drugs like sodium glucose co-transporter-2 (SGLT-2) inhibitor drug empagliflozin, and Dipeptidylpeptidase-4 (DPP-4) inhibitor drug linagliptin.
“When it comes to diabetes, we have a complete range of products. One thing, we are missing is GLP 1 analog, which we are looking to bring into our portfolio,” Rajeev Sibal, president, India Region Formulations, Lupin, told Mint.
GLP 1 or glucagon-like peptide-1 receptor agonist helps normalise blood sugar levels.
In India, GLP 1 class of drugs is sold by Novo Nordisk, Eli Lily and Co. and Sanofi, in injectable form.
According to data from healthcare information provider QuintilesIMS, Novo Nordisk sells its drug through partner Abbott India under brand name Victoza, Eli Lily under the brand Trulicity, and Sanofi under the brand Lyxumia. The prices of these injections are in the range of Rs3,100 to Rs4,000.
In the area of diabetes, Lupin has had in-licensing deals with US-based Eli Lilly and German company Boehringer Ingelheim GmbH over the last two-three years to bring in new classes of drugs to the Indian market.
The overall market size of di Continue reading

Rate this article
Total 1 ratings
How to Count Carbs for Diabetes Management

How to Count Carbs for Diabetes Management

Most of my clients with diabetes count carbs to help manage their blood sugar levels. It’s one of many tools to help them with meal planning.
What is carb counting?
With carb counting, you estimate the amount of carbohydrate in your food with the goal of staying within a predetermined range or allowance for each meal and snack.
Carb counting does NOT mean avoiding carbohydrates. It does NOT mean that carbs are bad. Carbohydrates are a nutrient. They are not a type of food. And many, many health-boosting, disease-fighting foods are rich in carbohydrates. Think fruit, quinoa, yogurt, milk, vegetables, black beans, chickpeas, limas, brown rice and a million more!
The beauty of carb counting is that it gives you tons of flexibility. You can choose your carbohydrates from any type of food. This is also the downfall of carb counting. I sure don’t want you to focus on carb counts without paying attention to nutrition. This is just like limiting calories to lose weight, but favoring veggie chips and diet pudding over the foods your body really needs like fruit, nuts and salmon.
Why is it a good idea to count carbs?
Don’t avoid carbs. Count them!
Eating a lot of carbohydrate at one time raises blood sugar a lot, and eating just a little carbohydrate, raises blood sugar less. Many people with diabetes aim for about 45 – 60 grams of carbohydrate per meal and 15 grams or so per snack, but the amount that’s right for you may be more or less. And that depends on your medications, activity level, blood sugar goals and other things. I like to look at my patients’ food records a Continue reading

First patient in diabetes trial no longer needs insulin therapy

First patient in diabetes trial no longer needs insulin therapy

MIAMI, Sept. 10 (UPI) -- The first patient to receive therapeutic delivery of islet cells in a new diabetes study no longer needs insulin therapy to control type 1 diabetes, according to doctors at the University of Miami's Diabetes Research Institute.
The patient, Wendy Peacock, 43, has been giving herself insulin injections to control diabetes since she was diagnosed with the condition at age 17. Since she had the minimally-invasive procedure on August 18, Peacock has been off insulin, because her body is producing it naturally, and she no longer has the dietary restrictions that accompany type 1 diabetes.
Type 1 diabetes is caused by inadvertent destruction of insulin-producing islet cells in the pancreas by the immune system. While previous experimental treatments that involved the replacement of these cells has allowed patients to live without the need for insulin-replacement therapy for up to a decade, the goal is for better delivery of the cells to make the surgical treatment permanent -- effectively curing the condition.
"The technique has been designed to minimize the inflammatory reaction that is normally observed when islets are implanted in the liver or in other sites with immediate contact to the blood," said Dr. Camillo Ricordi, director of the DRI and a professor of biomedical engineering, microbiology, and immunology at the University of Miami, in a press release. "If these results can be confirmed, this can be the beginning of a new era in islet transplantation. Our ultimate goal is to include additional technologies to prevent the need for life-long anti-r Continue reading

Common jab could hold key to finding cure for Type 1 diabetes

Common jab could hold key to finding cure for Type 1 diabetes

Scientists are convinced the debilitating effects of Type 1 diabetes can be reversed with a cheap jab used to combat tuberculosis.
Unlike lifestyle-driven Type 2 diabetes, which is often linked to obesity, Type 1 is an auto immune disease that, until now, was thought to be incurable.
But a major breakthrough could see the chronic condition - known as early onset diabetes - wiped out within years.
Researchers think the generic Bacillus Calmette–Guerin (BCG) jab, administered to tens of millions of children each year, can help regenerate insulin-making cells, effectively reversing the condition.
The BCG vaccine is up to 80 per cent effective in preventing TB for 15 years.
Results of initial tests in those who had diabetes for an average of 15 years suggest insulin production can be restored, albeit briefly, by a simple booster injection.
This is a cheap and generic drug that could be very effective and we’ve been saying that message over and over ahead since the start
The astonishing outcome is considered so significant £12million is being ploughed into a second five-year trial.
Experts in Britain described the quantum leap as “very exciting”.
Dr Denise Faustman, who is leading the research, said: “We decided to use a safe 100-year-old vaccine to make this happen and we’ve found that it works.
“We saw early signs that even at low doses of this vaccine the bad white blood cells that were killing the pancreas were killed and the good white blood cells that quiet down Type 1 diabetes were up-regulated.
“This is a cheap and generic drug that could be very effecti Continue reading

Holy Basil for the Treatment of Diabetes

Holy Basil for the Treatment of Diabetes

Ocimum sanctum, commonly referred to as holy basil, is an herb that is native to India; Ayurvedic medicine regards it as one of the most important plants. It is now widely grown throughout the world and can be eaten as a food or taken as a supplement. The leaves, stems, seeds and oils are all used medicinally.Many people with type 1 and type 2 diabetes use it to help lower high blood glucose levels.
Video of the Day
May Increase Insulin
Diabetes is a disorder characterized by chronic high blood glucose levels. There are two categories of diabetes. Type 1 individuals are unable to produce the hormone insulin and are therefore dependant on insulin injections. Type 2 diabetics make insulin but they either do not make enough, or they are insensitive to it. Some researchers theorize that holy basil can help to increase insulin secretion in type 2 diabetics, says Laura Shane-Mcwhorter in the book “The American Diabetes Association: Guide to Herbs and Nutritional Supplements.” Unfortunately there have not been enough rigorous studies to either confirm or disprove this theory.
Reducing Glucose Levels
Holy basil may also help to lower fasting and post-meal blood glucose levels. There was a study done on 40 type 2 diabetics, who were asked to stop all of their diabetes medications. Half of the patients were given 2.5 g of holy basil leaf powder daily, and the other half were given a placebo for four weeks. The groups were closely monitored and at the end of the study, holy basil was found to reduce fasting blood glucose levels by approximately 17.6 percent, and post-meal blood gl Continue reading

No more pages to load

Popular Articles

  • U.S. FDA approves new diabetes drug from Merck and Pfizer

    (Reuters) - A new drug developed by Merck & Co and Pfizer Inc won U.S. approval on Wednesday to treat type II diabetes, the Food and Drug Administration said, adding another competitor to a growing class of treatments. The oral drug, known generically as ertugliflozin, will be sold under the brand name Steglatro and compete with AstraZeneca Plc’s Farxiga, Johnson & Johnson’s Invokana and Eli L ...

  • A New Drug May Be Able to Completely Reverse Diabetes

    Scientists have used a new drug to reverse diabetes in mice. The drug inhibits the enzyme LMPTP, which contributes to the development of Type 2 diabetes by weakening the body's sensitivity to the hormone. Defining Diabetes In the global community, the number of people with diabetes has been on the rise since 1980, with 422 million people diagnosed by 2014. The U.S. alone has experienced a substant ...

  • New diabetes drug may also treat obesity

    Semaglutide is a compound that's already being developed as a treatment for diabetes, by Danish pharmaceutical company Novo Nordisk. According to a new study conducted by scientists from the University of Leeds, however, it may serve another valuable purpose – it could greatly aid the obese is losing weight. The chemical structure of semaglutide is very similar to that of GLP-1, a naturally-occu ...

  • New diabetes research takes a page from the past with a drug from the 1950s | Miami Herald

    Prior to Daniel Dyner having open-heart surgery four years ago, he appeared to be in great health. He had just moved to Key Biscayne from Venezuela, where he spent his time sailing around the world on solo trips to places like Trinidad, the Mediterranean and the coast of Africa. He swam nearly a mile every day and kept a strict diet. The 69-year-old Dyner was on the first lap of his daily swim in ...

  • Johnson & Johnson’s new diabetes drug linked to coma and death

    A Philadelphia man is suing Johnson & Johnson, claiming the pharmaceutical giant’s diabetes drug, Invokana, damaged his kidneys. Invokana is made by Janssen Pharmaceuticals, a Johnson & Johnson subsidiary. The commonly-prescribed drug had only been on the market for two years before the U.S. Food and Drug Administration determined it caused “too much acid in the blood and serious urinary tract ...

  • New drug treats root cause of type 2 diabetes, could reverse the disease

    A modified version of niclosamide, a drug that currently treats intestinal parasites, could be the key to reversing type 2 diabetes, according to new research from a Rutgers professor. Victor Shengkan Jin reports that one of the major causes of insulin resistance is excessive fat in the liver, which prevents the body from absorbing glucose and using it as fuel. The new drug, however, burns away th ...

  • Vaccine will cure diabetes: Scientists close to finding new wonder drug

    Launching the project today, they believe the research will result in an effective vaccine to combat Type 1 diabetes. Dr Alasdair Rankin, Diabetes UK’s director of research, said: “This research is hugely exciting because it has the potential to transform the lives of hundreds of thousands of people living with Type 1 diabetes, as well as leading us towards a longed-for cure.” The vaccine wo ...

  • Study: New oral drug helps control glucose, reduces need for insulin in patients with type 1 diabetes

    Study: New oral drug helps control glucose, reduces need for insulin in patients with type 1 diabetes A University of Colorado Anschutz Medical Campus study finds sotagliflozin helps control glucose and reduces the need for insulin in patients with type 1 diabetes . Principal results were published today in the New England Journal of Medicine of a global Phase 3 clinical trial in patients with ...

  • Pharmaceutical giant Novo Nordisk to invest £115m in a new UK drug research centre in post-Brexit 'vote of confidence'

    Danish pharmaceutical giant Novo Nordisk is to invest about £115m over 10 years in a new research centre in Oxford, in a move described by the government as a “vote of confidence” in post-Brexit Britain. About 100 scientists will work at the centre, investigating new approaches to treating type-2 diabetes. David Gauke, chief secretary to the Treasury, said that the move was a “vote of confi ...

Related Articles